Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 18.29%.

  • Theravance Biopharma's EBITDA Margin rose 931500.0% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.44%, marking a year-over-year increase of 1188400.0%. This contributed to the annual value of 72.92% for FY2024, which is 246600.0% up from last year.
  • As of Q3 2025, Theravance Biopharma's EBITDA Margin stood at 18.29%, which was up 931500.0% from 209.3% recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's EBITDA Margin peaked at 7361.3% during Q3 2022, and registered a low of 1038.96% during Q1 2022.
  • In the last 5 years, Theravance Biopharma's EBITDA Margin had a median value of 88.29% in 2025 and averaged 206.33%.
  • Per our database at Business Quant, Theravance Biopharma's EBITDA Margin soared by 76288600bps in 2022 and then plummeted by -74179400bps in 2023.
  • Over the past 5 years, Theravance Biopharma's EBITDA Margin (Quarter) stood at 375.8% in 2021, then skyrocketed by 68bps to 119.0% in 2022, then soared by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then soared by 137bps to 18.29% in 2025.
  • Its EBITDA Margin was 18.29% in Q3 2025, compared to 209.3% in Q2 2025 and 88.29% in Q1 2025.